Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.

Autor: Taira N; Department of Breast and Endocrine Surgery, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan. ntaira@md.okayama-u.ac.jp., Kashiwabara K; Clinical Research Promotion Center, University of Tokyo Hospital, Tokyo, Japan., Tsurutani J; Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan., Kitada M; Breast Disease Center, Asahikawa Medical University Hospital, Hokkaido, Japan., Takahashi M; Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan., Kato H; Department of Breast Surgery, Teine Keijinkai Hospital, Hokkaido, Japan., Kikawa Y; Department of Breast Surgery, Kansai Medical University Hospital, Osaka, Japan., Sakata E; Department of Breast Surgery, Niigata City General Hospital, Niigata, Japan., Naito Y; Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan., Hasegawa Y; Department of Breast Surgery, Hirosaki Municipal Hospital, Aomori, Japan., Saito T; Department of Breast Surgery, Japanese Red Cross Saitama Hospital, Saitama, Japan., Iwasa T; Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan., Takashima T; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan., Aihara T; Breast Center, Aihara Hospital, Osaka, Japan., Mukai H; Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan., Hara F; Breast Oncology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Jazyk: angličtina
Zdroj: Breast cancer (Tokyo, Japan) [Breast Cancer] 2022 Jan; Vol. 29 (1), pp. 186-188.
DOI: 10.1007/s12282-021-01296-z
Databáze: MEDLINE